Short Description Insilico Medicine CEO using generative AI for drug discovery.
Description Alex Zhavoronkov pioneered deep‑learning pipelines that design novel small‑molecule therapeutics in days. Insilico’s AI‑generated fibrosis inhibitor advanced to Phase I within 30 months, showcasing platform speed. He organizes the annual ARDD conference and publishes on aging clocks, biomarkers, and AI investment trends.
Platform Reach LinkedIn, X, Conferences, PubMed